Hernández Quijano Tomás, Illanes Aguiar Berenice, Salas Linares Natividad, Alarcón Romero Luz del Carmen, Hernández Valencia Marcelino
Unidad de Investigación Médica en Enfermedades Endocrinas del Hospital de Especialidades del Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, DF México.
Ginecol Obstet Mex. 2006 Jun;74(6):317-26.
Molecular studies have shown that oncogenic genotypes of human papillomavirus (HPV) are the main risk factor for cervical cancer development. Sub-clinical wound does not cause symptoms and is diagnosed by colposcopy or histology, in addition the latent infection is associated with the presence of DNA of the HPV, but when clinical and histological abnormalities are not presented only molecular techniques can detect this infection.
To determine if complementary processing with imiquimod, recent medicament with powerful antiviral activity in vitro as in vivo, reduces the cervical persistence of HPV.
This study was carried out with 87 patients, who had antecedents of HPV cervical and intraepithelial wound with low degree. Patients were divided as follows: treated with cryotherapy, cervical loop electrosurgical and imiquimod, all with diagnosis by cervical cytology, colposcopy and polymerase chain reaction (PCR) for HPV. At 3, 6 and 12 months after the processing, PCR, cervical cytology and colposcopy control were carried out again.
Out of the 87 patients studied, 11% (10) patients treated with cervical cytology were positive for VPH; with colposcopy 8% (7) of patients and with PCR 40% (34) of patients; decreased persistence with combined methods of loop and imiquimod was obtained in 29% (5) patients; however, when utilized imiquimod alone, there were 55% (11) patients with persistence determined by PCR method.
Imiquimod appears to be beneficial in 45% of the patients, in contrast with efficacy reported until 85% in genitals and annals warts, in addition, the capacity of eliminating the viruses has been shown, therefore it is possible that its potential effect could be observed long-time. It is evident that the percentages of viral detection are improved for PCR method, compared with indirect methods as cervical cytology and colposcopy, which is favorable when virus serotypes are of high degree of transformation and ablative methods should be conservatives due to fertility motives.
分子研究表明,人乳头瘤病毒(HPV)的致癌基因型是宫颈癌发生的主要危险因素。亚临床损伤不会引起症状,通过阴道镜检查或组织学进行诊断,此外,潜伏感染与HPV的DNA存在相关,但当未出现临床和组织学异常时,只有分子技术才能检测到这种感染。
确定使用咪喹莫特进行辅助治疗(咪喹莫特是一种近期发现的在体内外均具有强大抗病毒活性的药物)是否能降低HPV在宫颈的持续感染。
本研究对87例有HPV宫颈感染及低度上皮内损伤病史的患者进行。患者分为以下几组:接受冷冻疗法、宫颈环形电切术和咪喹莫特治疗,所有患者均通过宫颈细胞学检查、阴道镜检查和HPV聚合酶链反应(PCR)进行诊断。在治疗后3个月、6个月和12个月,再次进行PCR、宫颈细胞学检查和阴道镜检查。
在研究的87例患者中,经宫颈细胞学检查,11%(10例)患者HPV呈阳性;经阴道镜检查,8%(7例)患者呈阳性;经PCR检查,40%(34例)患者呈阳性;采用环形电切术和咪喹莫特联合方法治疗后,29%(5例)患者的持续感染情况有所改善;然而,单独使用咪喹莫特时,通过PCR方法确定有55%(11例)患者存在持续感染。
咪喹莫特似乎对45%的患者有益,这与在生殖器疣和肛周疣中报道的高达85%的疗效形成对比,此外,已显示出其清除病毒的能力,因此有可能在长期观察到其潜在效果。显然,与宫颈细胞学检查和阴道镜检查等间接方法相比,PCR方法的病毒检测率有所提高,当病毒血清型具有高度转化性且出于生育动机消融方法应保守进行时,这是有利的。